-
Subject Areas on Research
-
2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
-
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
-
A histopathologic study of retinal arterial aneurysms.
-
A natural experiment in the quality of care in gout.
-
A reappraisal of the concept of an abnormality of glutamine metabolism in primary gout.
-
Acute gout presenting in the manubriosternal joint.
-
Agency and structure in the sociology of sickness.
-
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
-
Antihypertensive effectiveness of very low doses of hydrochlorothiazide: results of the PHICOG Trial.
-
Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid.
-
Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls.
-
Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease.
-
Biochemical profile of stone-forming patients with diabetes mellitus.
-
Circulating galectin-3 in infections and non-infectious inflammatory diseases.
-
Clinical Images: a not-so crystal-clear ankle mass.
-
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
-
Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation.
-
Colchicine--Update on mechanisms of action and therapeutic uses.
-
Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.
-
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
-
Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
-
Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
-
Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target?
-
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
-
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
-
Ethnic background has minimal impact on the etiology of nephrolithiasis.
-
Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
-
Familial hyperuricemia and renal insufficiency.
-
Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study.
-
Fine-needle aspiration cytology of articular and periarticular lesions.
-
Gout and the regulation of purine biosynthesis.
-
Gout as a source of sesamoid pain.
-
Gout management: let's get it right this time.
-
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.
-
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
-
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?
-
Gout, tophi and the wonders of NETs.
-
Gout: no longer the disease of kings.
-
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
-
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
-
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
-
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
-
Long-term colchicine administration leading to colchicine toxicity and death.
-
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
-
Migration and gout: the Tokelau Island migrant study.
-
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
-
Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?
-
OMERACT endorsement of measures of outcome for studies of acute gout.
-
Pegloticase for treating refractory chronic gout.
-
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
-
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
-
Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.
-
Progress in the pharmacotherapy of gout.
-
Quality of life and disability in patients with treatment-failure gout.
-
Reassessing serum urate targets in the management of refractory gout: can you go too low?
-
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
-
Refractory gout: what is it and what to do about it?
-
Renal calculi: pathogenesis, diagnosis, and medical therapy.
-
Rheumatologic manifestations of cancer.
-
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
-
Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
-
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
-
The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout.
-
The kinetics of intramolecular distribution of 15N in uric acid following administration of 15N-glycine: preferential labeling of N-(3+9) of uric acid in primary gout and a reappraisal of the "glutamine hypothesis".
-
The rheumatology of gout.
-
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
-
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
-
Uricase and other novel agents for the management of patients with treatment-failure gout.
-
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.
-
Keywords of People
-
Allen, Nancy Bates,
Professor Emeritus of Medicine,
Medicine, Rheumatology and Immunology
-
Ostbye, Truls,
Professor of Family Medicine and Community Health,
Family Medicine and Community Health
-
Preminger, Glenn Michael,
James F. Glenn, M.D. Distinguished Professor of Urology,
Surgery